Drugs & MedicationsPhysician Office Issues

DOCS INFLUENCED BY BIG PHARMA

Like most businesses, pharmaceutical manufacturers lobby their customers. For a company to sell its product, it must tell its customers how it’s product works, for what conditions it should be used, and why theirs is a better product than the competition’s. To do that, companies hire and train a cadre of salespeople who call on customers to “sell” them on the product. In the pharmaceutical world, the customer is the patient who ultimately purchases and consumes the drug, but between the salesperson and the consumer there exists the physician who acts as a buffer, or intermediary, and who first decides if the drug is right for the patient’s condition and prescribes it. It’s the doctor who first must be convinced that drug XYZ has an advantage over its competitors and should be purchased and taken by the patient. 

This patient advocacy role assumed by physicians has put them in the crosshairs of consumer  protection groups who take the position that physicians could not possibly make an unbiased decision and are improperly influenced by pharmaceutical salespeople to prescribe their drug. This attitude has subjected physicians and drug companies to all kinds of accusations of  biased prescribing because of all types of perks given to physicians intended to influence the prescribing habits of physicians. To state it bluntly, drug companies are “paying” doctors to prescribe their drugs and physicians are willing accomplices. 

These allegations and accusations have caused drug companies to revamp their approach to physician interaction, and what is and isn’t considered ethical in that relationship. What is appropriate, what is allowed, and what is not allowed is spelled out clearly in policy statements adopted and implemented by pharmaceutical companies. 

During my 40 years in practice I saw at least one drug rep in my office every day. Some days I saw a rep, or signed for samples, as many as 15 times. Nearly every day, a drug rep brought lunch to my office, and during that lunch, the rep gave his/her promotional spiel that always led to a spirited discussion about why I should or shouldn’t prescribe their drug. Pharmaceutical companies also sponsored dinner meetings during which an invited (and paid) speaker gave an educational and promotional talk on the drug they were selling. My wife and I attended dozens of those. Since I had a very busy practice and was one of the bigger prescribers, I was one of the drug reps targets. That led to a lot of Thursday afternoon rounds of golf. But I never received any direct cash payment for prescribing any drug.

A lot of medical researchers have made it their goal in life to investigate the relationship between drug companies and physicians. They hope to eliminate a company’s attempts by various means to get doctors to prescribe their products when a less expensive alternative is available. To give you an idea of the magnitude of this effort, Cochrane Reviews compiled information from 93 studies all of which sought to correlate pharmaceutical company contact with physicians and how it affected their prescribing habits. (Cochrane is a publication that gathers research data on a medical subject and consolidates it into a synopsis). For Cochrane to review at least 93 articles on the subject, you know it’s an area of great importance.

Cochrane examined “three ways pharmaceutical companies engage with physicians: 

  1. Advertising and education-seminars, promotional brochures, mailings.
  2. Gifts and payments-I never received any payment.
  3. Free samples-I used them all the time. 

They studied this subject in-depth and reached the following conclusion: “doctors who accepted gifts and payments from industry showed the strongest correlations with certain prescribing outcomes….the more interactions doctors had [with drug companies], the less appropriate their prescribing was and the more prescriptions they wrote.” Industry-sponsored meals” had a “particularly pronounced effect….those who received more meals prescribed more promoted products.” 

Cochrane summarized their conclusions with the following statements: 

  1.  “We cannot say that pharmaceutical marketing and promotion caused changes to doctors’ prescribing.
  2. We are confident that inappropriate prescribing was higher among doctors who received gifts and payments, and that they wrote more prescriptions than doctors who did not receive gifts and payments.
  3. The more interactions doctors had with pharmaceutical companies, the less appropriate their prescribing was and the more prescriptions they wrote. 
  4. We are “very uncertain if free medicine samples from pharmaceutical companies to doctors affect prescribing appropriateness, quantity, and costs.”

“Doctors tend to rationalize their prescribing decisions telling themselves drug XYZ is the best for the situation rather than recognizing the “psychological dynamics” involved after hearing the reps presentation just a few hours earlier. Physicians, myself included, feel they are immune from the subliminal influence a conversation with a rep can cause. I know I prescribed XYZ because I had samples and remember what the rep said about XYZ being better than drug ABC. There is a problem with physicians believing they can’t be influenced by the reps comments. I know I was, but I told myself I was prescribing XYZ because I decided it was the right choice for Mr. Smith. 

For many years there has been a movement to restrict drug company access to physicians. Many institutions already restrict, or even prohibit, interaction with drug reps. Some advocates call for a “hard line approach” which amounts to a ban, and the 93 studies analyzed for the Cochrane review say the weight of evidence supports that policy. “This literature is so big and shows that these relationships change doctors’ behaviors….I always believed…… this would stop, [but] it hasn’t. It’s baked into the culture….it will not change until…..the federal government puts an end to it.” 

Reference: Weber S. Docs Exposed to Pharma Marketing Write More, Less Appropriate Scripts: Cochrane Review medscape.com 2026 October 22.

Cochrane Review: How does pharmaceutical company marketing and promotion influence doctors’ prescribing behavior? Plain language summary. medscape.com 2026 October. 

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button